CARBIDOPA

Post-LOE

Alvogen

ANDAORALTABLET

Approved

Jan 2016

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

CARBIDOPA by Alvogen is orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Approved for parkinson's disease, post-encephalitic parkinsonism, parkinsonism and 2 more indications. First approved in 2016.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

orally, it is rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system. Carbidopa inhibits the decarboxylation of peripheral levodopa, making more levodopa available for delivery to the brain.…

Indications (5)

Parkinson's disease post-encephalitic parkinsonism

Worked on CARBIDOPA at Alvogen? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Clinical Trials (20)

NCT07382440N/ARecruiting

A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium

Started Mar 2026

120 enrolled

Parkinson's Disease

NCT07227896N/ANot Yet Recruiting

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease

Started Mar 2026

100 enrolled

Parkinson's Disease

NCT07313176N/ARecruiting

Long Term Effectiveness of Levodopa-Entacapone-Carbidopa Intestinal Gel in Participants With Advanced Parkinson's Disease

Started Jan 2026

215 enrolled

Advanced Parkinson Disease

NCT07284342N/ARecruiting

A Study to Assess Change in Sleep Disturbances of Adult Participants With Advanced Parkinson's Disease Receiving Subcutaneous Foslevodopa/Foscarbidopa

Started Nov 2025

103 enrolled

Advanced Parkinson's Disease

NCT06965374N/ARecruiting

Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson Disease

Started Jun 2025

270 enrolled

Parkinson Disease